Literature DB >> 15333677

GABAB receptor antagonist-mediated antidepressant-like behavior is serotonin-dependent.

David A Slattery1, Sandrine Desrayaud, John F Cryan.   

Abstract

There is an emerging body of data purporting a role of gamma-aminobutyric acid (GABA) in the pathophysiology of mood disorders. However, the role of metabotropic GABA(B) receptors in depression is not well defined. The modified forced swim test has recently emerged as an excellent tool to assess behaviorally the role of monoamines in antidepressant action. To assess the role of GABA(B) receptors in antidepressant-related behavior, we examined a number of selective GABA(B) receptor ligands (novel positive modulators and antagonists) on behavior in the modified forced swim test. We demonstrate that the selective GABA(B) receptor antagonists CGP56433A [[3-{1-(S)-[{3-cyclohexylmethyl)hydroxy phosphinyl}-2-(S) hydroxy propyl]amino}ethyl]benzoic acid; 1-10 mg/kg] and [3-[[1-(S)-3-dichlorophenyl)ethyl]amino]-2-(S)-hydroxy-propyl]phenylmethyl-phosphinic acid hydrochloride; 3-10 mg/kg] had a similar profile to the selective serotonin reuptake inhibitor fluoxetine; they decreased immobility and increased swimming behavior. The tricyclic antidepressant desipramine decreased immobility but increased climbing behavior. In contrast, the novel GABA(B) receptor-positive modulator GS39783 (10-40 mg/kg) did not display antidepressant-like activity in the modified forced swim test. To further assess the possible interaction between GABA(B) receptor antagonism and serotonin, rats were pretreated with the tryptophan hydroxylase inhibitor para-chlorophenylalanine. 5-Hydroxytryptamine depletion (>90%) abolished the antidepressant-like behavior of CGP56433A (10 mg/kg) by attenuating the increase in swimming. Together, these data demonstrate that GABA(B) receptor antagonists via an interaction with the serotonergic system display antidepressant-like properties and therefore represent a novel approach for the treatment of depression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15333677     DOI: 10.1124/jpet.104.073536

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

1.  Evaluation of reward processes in an animal model of depression.

Authors:  David A Slattery; Athina Markou; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2006-12-20       Impact factor: 4.530

2.  Both GABA(B) receptor activation and blockade exacerbated anhedonic aspects of nicotine withdrawal in rats.

Authors:  Styliani Vlachou; Neil E Paterson; Sebastien Guery; Klemens Kaupmann; Wolfgang Froestl; Deboshri Banerjee; M G Finn; Athina Markou
Journal:  Eur J Pharmacol       Date:  2011-01-22       Impact factor: 4.432

3.  Gender-specific effects of CGP 55845, GABAB receptor antagonist, on neuromuscular coordination, learning and memory formation in albino mouse following neonatal hypoxia-ischemia insult.

Authors:  Quratul Ane Gillani; Atif Akbar; Muhammad Ali; Furhan Iqbal
Journal:  Neurol Sci       Date:  2015-04-07       Impact factor: 3.307

4.  Blunted 5-HT1A receptor-mediated responses and antidepressant-like behavior in mice lacking the GABAB1a but not GABAB1b subunit isoforms.

Authors:  Laura H Jacobson; Daniel Hoyer; Dominique Fehlmann; Bernhard Bettler; Klemens Kaupmann; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2017-01-09       Impact factor: 4.530

5.  GABA(B) receptor modulation of serotonin neurons in the dorsal raphé nucleus and escalation of aggression in mice.

Authors:  Aki Takahashi; Akiko Shimamoto; Christopher O Boyson; Joseph F DeBold; Klaus A Miczek
Journal:  J Neurosci       Date:  2010-09-01       Impact factor: 6.167

6.  Type B GABA receptors contribute to the restoration of balance during vestibular compensation in mice.

Authors:  R Heskin-Sweezie; H K Titley; J S Baizer; D M Broussard
Journal:  Neuroscience       Date:  2010-04-13       Impact factor: 3.590

Review 7.  The GABAβ receptor as a target for antidepressant drug action.

Authors:  Subroto Ghose; Michelle K Winter; Kenneth E McCarson; Carol A Tamminga; Salvatore J Enna
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

8.  Variations in the nature of behavioral experience can differentially alter the consequences of developmental exposures to lead, prenatal stress, and the combination.

Authors:  Deborah A Cory-Slechta; Kian Merchant-Borna; Joshua L Allen; Sue Liu; Douglas Weston; Katherine Conrad
Journal:  Toxicol Sci       Date:  2012-08-28       Impact factor: 4.849

9.  Fluoxetine partly exerts its actions through GABA: a neurochemical evidence.

Authors:  M Zafer Gören; Esra Küçükibrahimoglu; Kemal Berkman; Berna Terzioglu
Journal:  Neurochem Res       Date:  2007-05-08       Impact factor: 3.996

Review 10.  Innovative approaches for the development of antidepressant drugs: current and future strategies.

Authors:  Lee E Schechter; Robert H Ring; Chad E Beyer; Zoë A Hughes; Xavier Khawaja; Jessica E Malberg; Sharon Rosenzweig-Lipson
Journal:  NeuroRx       Date:  2005-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.